Episode

Age-less Innovations: Peptides and Modern Medicine

Podcast
The Science of Age-less Living
Published
Aug 5, 2025
Duration seconds
1992
Processing state
not_requested
Canonical source
https://rss.com/podcasts/the-science-of-age-less-living/2153435
Audio
https://content.rss.com/episodes/319089/2153435/the-science-of-age-less-living/2025_08_05_20_17_43_bc9f5142-7205-464c-8952-e3b084a00c52.mp3
JSON
/v1/public/podcasts/the-science-of-age-less-living-7235688/episodes/age-less-innovations-peptides-and-modern-medicine
Markdown
/podcast/the-science-of-age-less-living-7235688/age-less-innovations-peptides-and-modern-medicine.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-science-of-age-less-living-7235688/episodes/age-less-innovations-peptides-and-modern-medicine/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-science-of-age-less-living-7235688/age-less-innovations-peptides-and-modern-medicine.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

This podcast episode of "The Science of Age-less Living," hosted by Dr. Ethan , delves into the burgeoning world of peptide therapies and their role in modern medicine, particularly in the context of longevity and wellness. The discussion highlights the science behind peptides—short chains of amino acids with targeted effects on bodily processes—and contrasts their rapid rise in the wellness community with the traditional, cautious approach of Big Pharma. Through real-world case studies, market data, and expert insights, the episode explores whether peptides are a disruptive force or a complementary innovation, examining regulatory challenges, safety concerns, and rampant misinformation in the marketplace. Ultimately, the narrative underscores that while peptides hold immense promise for age-less living and transformative healthcare, their integration requires rigorous science, informed consumer choices, and collaboration between innovators and established pharmaceutical companies to maximize benefits and minimize risks.